Creatine Supplementation: What the Evidence Supports for Strength, Muscle & Performance

Research snapshot

Research Question: Which creatine outcomes are actually supported, and how should form, saturation strategy and safety context constrain the decision?
Main Finding: Creatine can provide incremental benefits for maximal strength, lean or fat-free mass and selected repeated high-intensity outcomes, but those endpoints are not interchangeable and do not establish universal performance or direct-hypertrophy effects.
Evidence Reviewed: 16 governed human evidence records spanning meta-analyses, controlled trials and safety syntheses, with explicit null, qualifying and contradictory endpoints retained.
Framework: Outcome target → exercise context → creatine form → saturation strategy → applicability and safety.
Protocol: Define the outcome first; preserve training context; separate lean mass from direct hypertrophy; match performance claims to tested endpoints; keep safety conclusions population-bounded.
Publication Status: SKP-007 v0.2 has passed scientific review, editorial approval and governed release readiness, and is activated for production deployment.

01 / Executive summary

Executive Summary

02 / Research question

Research Question

In generally healthy adults, what effects of creatine supplementation are supported for maximal strength, lean or fat-free mass, directly measured hypertrophy and repeated high-intensity performance, and how should creatine form, loading strategy and safety evidence constrain practical interpretation?

03 / Scientific context

Creatine has a strong evidence base, but the useful answer depends on the outcome being asked about.

Across resistance-training and performance evidence, creatine can provide incremental benefits for maximal strength, lean or fat-free mass and selected repeated high-intensity outcomes. Those findings are not interchangeable: lean-mass change is not the same measurement as direct contractile-muscle hypertrophy, repeated-sprint findings do not establish endurance benefit, and effects observed alongside resistance training do not mean supplementation replaces training. Form, saturation strategy, population and safety context also constrain practical meaning.

04 / Evidence review

Evidence Review

05 / Core insight

The strongest creatine decision is not 'creatine works'—it is knowing which outcome, form, strategy and population the evidence actually supports.

Creatine becomes decision-useful when maximal strength, lean mass, direct hypertrophy, repeated high-intensity performance and endurance are separated before interpretation. The same discipline applies to form selection, saturation strategy and safety: monohydrate is the evidence reference, loading changes speed of saturation rather than proving superior long-term efficacy, and reassuring healthy-adult safety evidence does not become universal medical clearance.

06 / Framework

Creatine Evidence-to-Decision Interpretation Framework

Canonical framework

Creatine Evidence-to-Decision Interpretation Framework

Interpret creatine decisions through outcome target, exercise context, creatine form, dosing/saturation strategy and applicability/safety context while preserving outcome-specific evidence and explicit non-claims.

01 / Outcome target

Separate maximal strength, lean mass, direct hypertrophy, repeated high-intensity performance and endurance.

02 / Exercise context

Keep resistance-training evidence distinct from supplementation without training.

03 / Creatine form

Use monohydrate as the evidence reference and require direct comparison for superiority claims.

04 / Saturation strategy

Separate faster tissue saturation from long-term strength, hypertrophy or performance efficacy.

05 / Applicability & safety

Check population, duration, adverse events, serum creatinine and filtration as distinct evidence dimensions.

Outcome → exercise context → form → saturation strategy → applicability/safety. Draft framework pending G5 scientific authority.

07 / Protocol

Creatine Decision Support Protocol

Practical protocol

Objective

Interpret whether creatine is relevant to a stated performance or muscle goal while preserving form, dosing, transferability and safety boundaries.

Audience

Generally healthy adults using non-clinical educational decision support.

Core principles

• Define the target outcome first.
• Preserve resistance-training context.
• Separate lean mass from direct hypertrophy.
• Match performance claims to tested endpoints.
• Use monohydrate as the evidence reference.
• Treat loading as a saturation-speed option rather than a superior-outcome rule.
• Apply explicit population and safety boundaries.

Recommendations

• State the outcome before judging whether creatine is evidence-relevant.
• Require direct comparative human evidence before accepting alternative-form superiority.
• Do not convert study dosing into one universal optimal dose.
• Keep serum creatinine interpretation separate from filtration outcomes.
• Stop at the evidence boundary for medically complex safety questions.

Limitations

• No universal optimal dose is established by this protocol.
• Loading is not required for long-term efficacy.
• Lean-mass gain is not identical to directly measured hypertrophy.
• High-intensity findings do not establish endurance improvement.
• Healthy-adult safety evidence does not establish universal medical safety.

Educational decision support only. Not diagnosis, treatment, individualized medical advice or authorization to ignore clinician guidance in kidney disease, pregnancy, medication use or other medically complex situations.

08 / Limitations

Boundaries that must remain visible

The evidence spans different ages, training states, endpoints, durations and measurement methods. Review-level evidence may overlap with primary trials and must not be counted as independent replication. Some influential creatine syntheses include industry funding, industry-affiliated authorship or professional/commercial relationships; those records should be interpreted alongside independently generated evidence and methodological quality rather than treated as automatically invalid or as fully independent replication. Lean or fat-free mass is not a direct measure of contractile hypertrophy. Repeated high-intensity performance cannot be generalized to endurance. Monohydrate's stronger evidence base does not prove every alternative form is inferior or identical. Loading changes time to saturation but does not establish superior long-term outcomes. Aggregate adverse-event and kidney-function evidence in generally healthy participants does not establish universal safety in kidney disease, pregnancy, pediatric use or medically complex populations. Cognition is outside SKP-007's governed publication scope.

• No universal optimal dose is established by this protocol.
• Loading is not required for long-term efficacy.
• Lean-mass gain is not identical to directly measured hypertrophy.
• High-intensity findings do not establish endurance improvement.
• Healthy-adult safety evidence does not establish universal medical safety.

09 / Practical takeaways

Practical Takeaways

• Treat creatine as evidence-relevant to maximal-strength goals when resistance training is part of the context, not as a substitute for training.
• Report lean-mass and direct-hypertrophy outcomes separately rather than translating one into the other.
• Match a performance claim to the tested endpoint; do not use generic 'performance improvement' language.
• Use monohydrate as the evidence reference while requiring direct comparative human evidence for alternative-form superiority claims.
• Treat loading as a speed-of-saturation option, not as a mandatory efficacy requirement.
• Keep creatinine and filtration separate and keep safety conclusions bounded to represented populations and durations.

10 / Scientific references

Scientific References

EVD-SKP007-001 — Desai I, Wewege MA, Jones MD, et al. J Strength Cond Res. 2024;38(10):1813-1821. Year: 2024. Study Type: Systematic Review / Meta-analysis. DOI: 10.1519/JSC.0000000000004862. PMID: 39074168.
EVD-SKP007-002 — Wang Z, Qiu B, Li R, et al. Nutrients. 2024;16(21):3665. Year: 2024. Study Type: Systematic Review / Meta-analysis. DOI: 10.3390/nu16213665. PMID: 39519498.
EVD-SKP007-003 — Forbes SC, Candow DG, Ostojic SM, Roberts MD, Chilibeck PD. Nutrients. 2021;13(6):1912. Year: 2021. Study Type: Systematic Review / Meta-analysis. DOI: 10.3390/nu13061912. PMID: 34199420.
EVD-SKP007-004 — Liu S, Huang N, Wu W, et al. Eur Rev Aging Phys Act. 2025;22:26. Year: 2025. Study Type: Systematic Review / Meta-analysis. DOI: 10.1186/s11556-025-00392-9. PMID: 41388441.
EVD-SKP007-005 — Sharifian G, Aseminia P, Heidary D, Esformes JI. Eur Rev Aging Phys Act. 2025;22(1):17. Year: 2025. Study Type: Systematic Review / Meta-analysis. DOI: 10.1186/s11556-025-00384-9. PMID: 41062952.
EVD-SKP007-006 — Glaister M, Rhodes L. Int J Sport Nutr Exerc Metab. 2022;32(6):491-500. Year: 2022. Study Type: Systematic Review / Meta-analysis. DOI: 10.1123/ijsnem.2022-0072. PMID: 36041731.
EVD-SKP007-007 — Fernández-Landa J, Santibañez-Gutierrez A, Todorovic N, Stajer V, Ostojic SM. Sports Med. 2023;53(5):1017-1027. Year: 2023. Study Type: Systematic Review / Meta-analysis. DOI: 10.1007/s40279-023-01823-2. PMID: 36877404.
EVD-SKP007-008 — Pashayee-Khamene F, Heidari Z, Asbaghi O, et al. J Int Soc Sports Nutr. 2024;21(1):2380058. Year: 2024. Study Type: Systematic Review / Meta-analysis. DOI: 10.1080/15502783.2024.2380058. PMID: 39042054.
EVD-SKP007-009 — Burke R, Piñero A, Coleman M, et al. Nutrients. 2023;15(9):2116. Year: 2023. Study Type: Systematic Review / Meta-analysis. DOI: 10.3390/nu15092116. PMID: 37432300.
EVD-SKP007-010 — Fazio C, Elder CL, Harris MM. J Strength Cond Res. 2022;36(9):2663-2670. Year: 2022. Study Type: Systematic Review. DOI: 10.1519/JSC.0000000000003873. PMID: 36000773.
EVD-SKP007-011 — Kreider RB, Jäger R, Purpura M. Nutrients. 2022;14(5):1035. Year: 2022. Study Type: Narrative Review. DOI: 10.3390/nu14051035. PMID: 35268011.
EVD-SKP007-012 — Hultman E, Söderlund K, Timmons JA, Cederblad G, Greenhaff PL. J Appl Physiol. 1996;81(1):232-237. Year: 1996. Study Type: Controlled Experimental Study. DOI: 10.1152/jappl.1996.81.1.232. PMID: 8828669.
EVD-SKP007-013 — Preen D, Dawson B, Goodman C, Beilby J, Ching S. Int J Sport Nutr Exerc Metab. 2003;13(1):97-111. Year: 2003. Study Type: Controlled Experimental Study. DOI: 10.1123/ijsnem.13.1.97. PMID: 12660409.
EVD-SKP007-014 — Kreider RB, et al. J Int Soc Sports Nutr. 2025. Safety of creatine supplementation: analysis of the prevalence of reported side effects in clinical trials and adverse event reports. Year: 2025. Study Type: Systematic Review. DOI: N/A. PMID: 40198156.
EVD-SKP007-015 — Kabiri Naeini E, Eskandari M, Mortazavi M, Gholaminejad A, Karevan N. BMC Nephrol. 2025;26(1):622. Year: 2025. Study Type: Systematic Review / Meta-analysis. DOI: 10.1186/s12882-025-04558-6. PMID: 41199218.
EVD-SKP007-016 — Tsiaras A, Loufopoulos G, Theodoridis X, Liakopoulos V, Poulia KA, Chourdakis M. J Ren Nutr. 2026. Online ahead of print. Year: 2026. Study Type: Systematic Review / Meta-analysis. DOI: 10.1053/j.jrn.2026.04.010. PMID: 42035842.

How to cite

TasteFromSoul. Creatine Supplementation: What the Evidence Supports for Strength, Muscle & Performance. SKP-007, version 0.2. Publisher: TasteFromSoul.

Version history

v0.2 — Production activation after G5 scientific approval, G6 editorial approval and G7 release readiness.
v0.2 — G5 scientific approval and G6 editorial approval granted after corrected-candidate re-review.
v0.2 — RP-11 scientific correction loop preserved outcome separation, explicit null/qualifying evidence, form/loading boundaries and population-bounded safety interpretation.
v0.1 — RP-09 publication candidate built from SKP-007-PUBSPEC-v0.1; RP-10 returned bounded corrections.